Senator Cassidy Cites Unanswered Questions on FDA Nominee Heidi Overton
Senator Bill Cassidy stated that unanswered questions remain regarding President Trump's nominee for the Food and Drug Administration, Dr. Heidi Overton, prior to a Senate committee vote on her nomination.

Baton Rouge, LA, November 15, 2026 —
WASHINGTON D.C. – Senator Bill Cassidy has indicated that significant questions persist concerning the nomination of Dr. Heidi Overton for the position of Food and Drug Administration (FDA) commissioner. These concerns were raised in the period leading up to a scheduled Senate committee vote on her candidacy.
Cassidy stated that the unanswered questions remain a point of consideration for the committee as they deliberate on Overton’s nomination. The specific nature of these outstanding questions was not detailed in the provided information. Similarly, the name of the specific Senate committee responsible for reviewing the nomination and conducting the vote was not provided.
The nomination of Dr. Heidi Overton, put forth by President Trump, is currently under review by the Senate. Her potential role as head of the FDA is subject to the committee’s approval, which requires addressing any outstanding concerns raised by committee members.
Details regarding the timeline for the committee vote, its outcome, or further information about Dr. Overton’s qualifications or the specific areas of concern articulated by Senator Cassidy were not available in the trend summary. The summary indicated only the existence of unanswered questions as a factor in the nomination process prior to the committee vote.
Story summarized from the original created by Ryan Mancini on thehill.com, see more information here.
Media gallery
